Kinfo
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc.

FULCNASDAQHealthcare·US · USD
$3.72
+0.02 (+0.54%)
Prices as of November 9, 2026 · market closed

Price

Key statistics

Valuation
Market cap282.61M USD
Enterprise value-31.26M USD
Trailing P/E-3.14
Forward P/E-6.76
PEG ratio-0.15
Price / sales0.00
Price / book0.91
Profitability
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on assets-19.59%
Return on equity-32.38%
Income (TTM)
Revenue0.00 USD
Gross profit-56.10M USD
EBITDA-85.40M USD
Net income-85.00M USD
Diluted EPS-$1.21
Rev. growth (YoY)0.00%
Balance sheet
Total cash318.84M USD
Total debt5.28M USD
Debt / equity1.70
Current ratio31.35
Book value / share$4.07
Cash flow (TTM)
Operating cash flow-65.78M USD
Levered free cash flow-37.37M USD
Shares & price
Shares outstanding76.29M
Float63.49M
Held by institutions101.95%
Beta2.77
50-day MA$3.75
200-day MA$5.69
52-week high$15.74
52-week low$2.83
Dividends
Forward rate
$0.00
Yield
0.00%
Payout ratio
0.00%
Frequency
Unknown
Earnings (EPS)
DateEst.ActualSurprise2026-07-30-0.22-0.22+0.00%2026-04-27-0.30-0.25+16.67%2026-02-24-0.30-0.31−3.33%2025-10-29-0.29-0.31−6.90%2025-09-210.380.48+26.32%
About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases. The company’s work centers on gene regulation and epigenetic control, using its discovery platform to identify drug targets that may address the root causes of disease rather than only managing symptoms. Its lead clinical program, pociredir, is designed to increase fetal hemoglobin expression and is being studied for sickle cell disease. Fulcrum Therapeutics also advances research programs in other serious hematologic and rare disorders, including beta-thalassemia and inherited aplastic anemias, while maintaining a broader focus on areas of high unmet medical need. Based in Cambridge, Massachusetts, Fulcrum Therapeutics plays a specialized role in the biotechnology market as a developer of precision medicines for challenging diseases with limited treatment options.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Alexander C. Sapir
Employees
9
Headquarters
Cambridge, MA, United States

Frequently asked questions about Fulcrum Therapeutics, Inc.